Marksans Pharma updates acquisition of QliniQ B.V.
On 16 Jun 2026, Marksans Pharma Limited filed a General Updates notification with the NSE regarding an acquisition of QliniQ B.V., a Netherlands-based entity. The intimate does not specify transaction value, consideration structure, conditions precedent or expected closure. Further details would be available in full exchange intimations or official company announcements.
Why it mattersCross-border pharma M&A involving Indian listed entity requires corroboration of FEMA/RBI approval and CCI clearance thresholds; verify full intimation schedules and company press release for deal certainty.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives – Marksans Pharma Limited (16 Jun 2026) · official
- NSE Limited – Corporate Announcements Portal · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026